Subtype
Clear Cell Renal Cell Carcinoma
CI-CAN-00004976CCRCCExplore in graph →
114 active trials2 approved drugs19 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004976CCRCCExplore in graph →
Clinical trials
247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05879471 | 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 39 | Peking Union Medical College HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion |
| unknown |
| Phase 2 |
| 40 |
| Peking Union Medical College HospitalOTHER |
| 1 |
| Jul 13, 2023 |
| clinicaltrials |
| NCT05879510 | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | unknown | Phase 2 | 63 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma(KEYPAD) | unknown | Phase 2 | 59 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 | clinicaltrials |
| NCT04995016 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma(PANDORA) | unknown | Phase 2 | 18 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04958473 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer(SAARCC) | unknown | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT03987698 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03592199 | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib(SuAx) | unknown | Phase 2 | 7 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02022787 | Value of Various Chemokines in the Detection and Follow up of RCC | unknown | — | 30 | Carmel Medical CenterOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01791387 | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC(DILIGENCE-1) | unknown | Phase 2 | 30 | Auckland District Health BoardOTHER_GOV | 1 | Feb 3, 2015 | clinicaltrials |
| NCT01069770 | Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) | unknown | Phase 2 | 32 | Korean Urological Oncology SocietyOTHER | 1 | Jun 23, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2024source: clinicaltrials